Technical Analysis for ASNS - Arsanis, Inc.
|Grade||Last Price||% Change||Price Change|
ASNS closed up 6.38 percent on Thursday, July 19, 2018, on 1.6 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Aug 9
|See historical ASNS trend table...|
|Date||Alert Name||Type||% Chg|
|Jul 19||Slingshot Bearish||Bearish Swing Setup||0.00%|
|Jul 19||MACD Bullish Signal Line Cross||Bullish||0.00%|
|Jul 19||Narrow Range Bar||Range Contraction||0.00%|
|Jul 19||Wide Bands||Range Expansion||0.00%|
|Jul 19||Oversold Stochastic||Weakness||0.00%|
|Jul 18||New 52 Week Closing Low||Bearish||6.38%|
|Jul 18||Narrow Range Bar||Range Contraction||6.38%|
|Jul 18||New 52 Week Low||Weakness||6.38%|
|Jul 18||Wide Bands||Range Expansion||6.38%|
|Jul 18||Down 3 Days in a Row||Weakness||6.38%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Arsanis, Inc. is a United States-based company engaged in the discovery and development of monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. The Company's mAbs focus on specific pathogens and pathogenic processes. Its product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500. Its lead program, ASN100, is being studied to prevent hospital-acquired Staphylococcus aureus pneumonia in mechanically ventilated patients heavily colonized with Staphylococcus aureus in their respiratory tracts. Its ASN200 addresses the unmet medical need caused by drug-resistant extra-intestinal escherichia coli infections. Its ASN300 addresses the unmet medical need due to carbapenem-resistant klebsiella pneumoniae infections. Its ASN400 addresses the unmet medical need due to streptococcus pneumoniae, a leading cause of mortality among the elderly. The ASN500 program consisting of potent mAbs targeting respiratory syncytial virus (RSV), is in the discovery phase.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ASNS news...
|52 Week High||28.69|
|52 Week Low||2.94|
|200-Day Moving Average||0.0|
|50-Day Moving Average||13.5924|
|20-Day Moving Average||7.1525|
|10-Day Moving Average||3.381|
|Average True Range||1.036|
|Chandelier Exit (Long, 3 ATRs )||15.882|
|Chandelier Exit (Short, 3 ATRs )||6.048|
|Upper Bollinger Band||19.7203|
|Lower Bollinger Band||-5.4153|
|Percent B (%b)||0.34|
|MACD Signal Line||-3.4739|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||3.53|
|Resistance 3 (R3)||3.51||3.38||3.47|
|Resistance 2 (R2)||3.38||3.28||3.39||3.45|
|Resistance 1 (R1)||3.27||3.23||3.33||3.29||3.43|
|Support 1 (S1)||3.03||3.04||3.09||3.05||2.91|
|Support 2 (S2)||2.90||2.99||2.91||2.89|
|Support 3 (S3)||2.79||2.90||2.87|
|Support 4 (S4)||2.81|